Supported pulmonary surfactant bilayers on silica nanoparticles: formulation, stability and impact on lung epithelial cells

International audienceStudies have shown that following exposure to particulate matter, the ultrafine fraction (< 100 nm) may deposit along the respiratory tract down to the alveolar region. To assess the effects of nanoparticles in the lungs, it is essential to address the question of their biophysicochemical interaction with the different pulmonary environments, including the lung lining fluids and the epithelia. Here we examine one of these interactive scenarios and study the role of supported lipid bilayers (SLB) on the fate of 40 nm fluorescent silica particles towards living cells. We first study the particle phase behavior in presence of Curosurf ® , a pulmonary surfactant substitute used in replacement therapies. It is found that Curosurf ® vesicles interact strongly with the nanoparticles, but do not spontaneously form SLBs. To achieve this goal, we use sonication to reshape the vesicular membranes and induce the lipid fusion around the particles. Centrifugal sedimentation and electron microscopy are carried out to determine the optimum coating conditions and layer thickness. We then explore the impact of surfactant SLBs on the cytotoxic potential and interactions towards a malignant epithelial cell line. All in vitro assays indicate that SLBs mitigate the particle toxicity and internalization rates. In the cytoplasm, the particle localization is also strongly coating dependent. It is concluded that SLBs profoundly affect cellular interactions and functions in vitro and could represent an alternative strategy for particle coating. The current data also shed some light on potential mechanisms pertaining to the particle or pathogen transport through the air-blood barrier